Mitochondrial citrate export emerges as a control point for the SASP
Senescent cells do not simply stop dividing; they switch on a secretory program that can reshape tissue biology for better or worse. In the work summarized here, mitochondrial citrate metabolism sits beside mtDNA-driven innate immune signaling as a required input for the senescence-associated secretory phenotype, or SASP. The key idea is unusually elegant: inflammatory transcription factors can be active, yet still fail to drive a full SASP unless the chromatin is metabolically licensed to respond.
This adds a second layer to the long-standing model of senescence. mtDNA released from damaged mitochondria through BAX/BAK-dependent minority mitochondrial outer membrane permeabilization activates cGAS–STING and downstream inflammatory transcription factors, but transcriptional activation alone does not explain why SASP loci remain open and productive over time. The new data place citrate export and histone acetylation at the center of that permissive state.
Histone acetylation at SASP loci depends on citrate-derived acetyl-CoA
In senescent human fibroblasts, mitochondrial depletion through Parkin-mediated mitophagy reduced H3K27ac at SASP genes and suppressed inflammatory mediators such as IL6 and CCL2 without impairing viability. The signal here is sharp: the cells remained alive and arrested, yet they lost much of their inflammatory output. Acetate supplementation, which replenishes acetyl-CoA through ACSS2, restored nuclear acetylation and partially rescued SASP expression, linking the transcriptional program directly to metabolite supply.
The pathway runs through the mitochondrial pyruvate carrier, SLC25A1, and ACLY. Across multiple senescence models, MPC, SLC25A1, and ACLY were upregulated, and pharmacologic or genetic disruption of MPC or SLC25A1 reduced SASP transcripts and secreted factors while leaving p16, p21, DNA-damage foci, and growth arrest intact. ACLY silencing produced a similar result. In practical mechanistic terms, citrate export appears to maintain a nucleocytosolic acetyl-CoA pool that keeps inflammatory chromatin accessible enough for sustained transcription.
One sentence captures the biology cleanly: the senescent cell can remain arrested while losing its inflammatory voice.
SLC25A1 inhibition separates inflammation from cell-cycle arrest
CTPI2, the SLC25A1 inhibitor used in the study, lowered cytosolic acetyl-CoA, reduced global nuclear acetylation, and diminished H3K27ac at SASP loci. It also abolished incorporation of glucose-derived carbon into histone acetylation. Yet mitochondrial morphology, oxidative phosphorylation, ATP production, and reactive oxygen species were largely unchanged. That pattern matters because it argues against broad mitochondrial failure as the explanation for the anti-inflammatory effect. Instead, the drug appears to intercept a specific citrate-export checkpoint that feeds epigenetic activation.
The distinction between suppressing inflammation and reversing senescence is biologically important. SLC25A1 inhibition did not erase the cell-cycle arrest program. p16 and p21 remained expressed, DNA-damage markers persisted, and proliferative blockade stayed in place. What changed was the secretory phenotype, not the senescent state itself. For any future therapeutic strategy, that separation raises the possibility of dampening chronic inflammatory burden without forcing senescent cells back into proliferation or killing them outright.
mtDNA signaling and metabolic licensing act as parallel inputs
Reciprocal perturbation experiments separated the mitochondrial metabolite pathway from mtDNA signaling. SLC25A1 inhibition suppressed SASP expression without reducing cytosolic mtDNA. In contrast, deletion of BAX and BAK1 reduced cytosolic mtDNA and SASP expression while leaving global histone acetylation and H3K27ac at SASP loci intact. STING inhibition also blocked inflammatory genes without lowering histone acetylation. The result is a two-input model rather than a single linear cascade.
Under this framework, mtDNA provides the inflammatory trigger, while citrate-derived acetyl-CoA provides the epigenetic license that lets the trigger produce a full transcriptional response. Acetate alone increased H3K27ac independently of STING activity. mtDNA transfection alone failed to increase histone acetylation in mitochondria-depleted senescent cells. When acetate and mtDNA were combined, SASP activation was greater than with either signal alone. This cooperative logic explains why senescent cells can sit in a poised state for long periods and then produce a robust inflammatory burst once both conditions are met.
Aging phenotypes improved in mice, but tissue responses were not uniform
The in vivo data extend the mechanistic findings into aged mice. CTPI2 delayed frailty, improved coordination and strength, preserved skeletal muscle integrity, and lowered circulating and tissue inflammatory factors. Single-nucleus multiome profiling showed reduced SASP transcription and chromatin accessibility in senescent-like muscle nuclei, yet their abundance did not measurably fall. In the liver, nuclear acetylation decreased in p16- and/or p21-positive, PCNA-negative cells without reducing the number of those cells.
These results support a mode of action that attenuates the harmful secretory output while sparing the senescent-cell population. Bone microarchitecture did not improve, and some hepatic responses differed by sex. Those findings keep the translational conversation grounded in biology rather than wishful extrapolation. Tissue-specific response, dosing window, and long-term safety remain unresolved.
The unresolved pore question still matters
The work also sharpens the mitochondrial side of the model. BAX/BAK-dependent miMOMP is already established as a route for mtDNA release in senescent cells, but VDAC-dependent mtDNA release has also been reported. Which pore dominates under particular stresses is still uncertain. The broader message is clear: mtDNA release and citrate export are distinct processes, yet they cooperate to sustain the SASP.
For cancer and aging biology, that cooperation carries real weight. Senescence can restrain proliferation and aid tumor suppression, but persistent SASP activity contributes to chronic inflammation and age-associated dysfunction. Targeting SLC25A1 offers one way to decouple those two sides of senescence. The remaining questions are concrete: which tissues benefit most, which stresses engage the same metabolic checkpoint, and how durable the anti-inflammatory effect will prove with longer treatment exposure.